Goods and bads of the endocannabinoid system as a therapeutic target: lessons learned after 30 years

M Maccarrone, V Di Marzo, J Gertsch, U Grether… - Pharmacological …, 2023 - Elsevier
The cannabis derivative marijuana is the most widely used recreational drug in the Western
world and is consumed by an estimated 83 million individuals (∼ 3% of the world …

The endocannabinoid system and the brain

R Mechoulam, LA Parker - Annual review of psychology, 2013 - annualreviews.org
The psychoactive constituent in cannabis, Δ9-tetrahydrocannabinol (THC), was isolated in
the mid-1960s, but the cannabinoid receptors, CB1 and CB2, and the major endogenous …

Endocannabinoid signalling in reward and addiction

LH Parsons, YL Hurd - Nature Reviews Neuroscience, 2015 - nature.com
Brain endocannabinoid (eCB) signalling influences the motivation for natural rewards (such
as palatable food, sexual activity and social interaction) and modulates the rewarding effects …

Chemical probes of endocannabinoid metabolism

JL Blankman, BF Cravatt - Pharmacological reviews, 2013 - Elsevier
The endocannabinoid signaling system regulates diverse physiologic processes and has
attracted considerable attention as a potential pharmaceutical target for treating diseases …

The pharmacological landscape and therapeutic potential of serine hydrolases

DA Bachovchin, BF Cravatt - Nature reviews Drug discovery, 2012 - nature.com
Serine hydrolases perform crucial roles in many biological processes, and several of these
enzymes are targets of approved drugs for indications such as type 2 diabetes, Alzheimer's …

Intracranial self-stimulation to evaluate abuse potential of drugs

SS Negus, LL Miller - Pharmacological reviews, 2014 - Elsevier
Intracranial self-stimulation (ICSS) is a behavioral procedure in which operant responding is
maintained by pulses of electrical brain stimulation. In research to study abuse-related drug …

Brain activity of anandamide: a rewarding bliss?

M Scherma, P Masia, V Satta, W Fratta… - Acta Pharmacologica …, 2019 - nature.com
Anandamide is a lipid mediator that acts as an endogenous ligand of CB1 receptors. These
receptors are also the primary molecular target responsible for the pharmacological effects …

Endocannabinoid-based therapies

D Piomelli, A Mabou Tagne - Annual Review of Pharmacology …, 2022 - annualreviews.org
The endocannabinoids are lipid-derived messengers that play a diversity of regulatory roles
in mammalian physiology. Dysfunctions in their activity have been implicated in various …

Mobilization of endocannabinoids by midbrain dopamine neurons is required for the encoding of reward prediction

MÁ Luján, DP Covey, R Young-Morrison… - Nature …, 2023 - nature.com
Brain levels of the endocannabinoid 2-arachidonoylglycerol (2-AG) shape motivated
behavior and nucleus accumbens (NAc) dopamine release. However, it is not clear whether …

Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders

K Ahn, DS Johnson, BF Cravatt - Expert opinion on drug discovery, 2009 - Taylor & Francis
Background: Fatty acid amide hydrolase (FAAH) is an integral membrane enzyme that
hydrolyzes the endocannabinoid anandamide and related amidated signaling lipids …